A Phase 3 interventional study of Dapagliflozin 5 mg and Dapagliflozin 10mg in Type 1 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 24 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-12.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 — 2 open to participants now, 5 under way, 2 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 1.
Among the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, this one is the 4th largest by enrollment, is one of 4 that started in 2015, is one of 7 in phase 3, and was the 6th registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:
St Vincent's Hospital Melbourne · Sites in Australia
Ages 24–85
Dasman Diabetes Institute · Sites in Kuwait, Qatar, Saudi Arabia
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 43 across the 23 interventional studies. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
18 studies in Diabetes Mellitus, Type 1 by AstraZeneca: none open now, none under way, none of them phase 3. Of 18 finished, 9 (50%) have results posted.
Among the 18 studies in Diabetes Mellitus, Type 1 by AstraZeneca, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2015, is one of 8 in phase 3, and was the 17th registered.
AstraZeneca’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 18 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will enroll eligible subjects into a long-term safety study (Part B).
Japanese male and female patients with T1DM and age 18 to 75 years, with inadequate glycemic control on insulin defined as HbA1c ≥ 7.5% and ≤ 10.5% at screening visit. As a condition of enrollment, subjects must be on a total daily insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to the screening visit. The study design of Part B is a randomized, open-label, 2 arm, parallel-group design. 140 Japanese subjects in total will be randomized in a 1:1 ratio into one of the two treatment arms; dapagliflozin 5 mg or dapagliflozin 10 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of thiazolidinediones within 6 months prior to the enrolment History of DKA requiring medical intervention within 1 month prior to the enrolment History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to the enrolment
Positive for surface antigen or anti- virus antibody Abnormal Free T4
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dapagliflozin tablet 5mg + adjustable insulin
Drug: Dapagliflozin 5 mg
dapagliflozin tablet 10mg + adjustable insulin
Drug: Dapagliflozin 10mg
Dapagliflozin, a blood glucose lowering drug. Oral dose
Dapagliflozin, a blood glucose lowering drug. Oral dose
Overall Adverse Event Summary
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
Time frame: From baseline to 52 weeks
Hypoglycemia
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
Time frame: From baseline to 52 weeks
Diabetic Ketoacidosis (DKA)
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
Time frame: From baseline to 52 weeks
Vital Signs (Heart Rate)
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
Time frame: From baseline to 52 weeks
ECGs
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
Time frame: From baseline to 52 weeks
Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
Time frame: From baseline to 52 weeks
Vital Signs (Blood Pressure)
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
Time frame: From baseline to 52 weeks
Adjusted Change From Baseline in HbA1c
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
Time frame: From baseline to 24/52 weeks
Adjusted Percent Change From Baseline in Total Daily Insulin Dose
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
Time frame: From baseline to 24/52 weeks
Adjusted Percent Change From Baseline in Body Weight
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
Time frame: From baseline to 24/52 weeks
Adjusted Change From Baseline in Glycoalbumin
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
Time frame: From baseline to 24/52 weeks
Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
Time frame: From baseline to 24/52 weeks
Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
Time frame: From baseline to 24/52 weeks
Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin
Time frame: From baseline to 24/52 weeks
Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin
Time frame: From baseline to 24/52 weeks
Proportion of Subjects Achieving HbA1c < 7.0 Percent
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin
Time frame: From baseline to 24/52 weeks
Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin
Time frame: From baseline to 24/52 weeks
| Milestone | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Started | 76 | 75 |
| Completed | 67 | 68 |
| Not completed | 9 | 7 |
| Withdrew: Study-specific withdrawal criteria | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Adverse event | 4 | 4 |
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
| Participants | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Adverse Events — At least one events | 67 | 55 |
| Related Adverse Events — At least one events | 23 | 22 |
| SAE — At least one events | 7 | 3 |
| AEs leading to discontinuation — At least one events | 4 | 4 |
| Death — At least one events | 0 | 0 |
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
| Participants | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Any Hypoglycemia Episodes — At least one events | 75 | 75 |
| Severe Hypoglycemia — At least one events | 2 | 5 |
| Documented Symptomatic Hypoglycemia — At least one events | 67 | 73 |
| Asymptomatic Hypoglycemia — At least one events | 60 | 64 |
| Probable Symptomatic Hypoglycemia — At least one events | 13 | 14 |
| Relative Hypoglycemia — At least one events | 14 | 11 |
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
| Participants | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Definite DKA — At least one events | 2 | 1 |
| Possible DKA — At least one events | 1 | 0 |
| Unlikely DKA — At least one events | 0 | 0 |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
| percent | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | -0.52 (-0.66 to -0.38) | -0.66 (-0.80 to -0.53) |
| Week 52 | -0.33 (-0.50 to -0.15) | -0.36 (-0.53 to -0.18) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
| percent change | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | -15.30 (-18.55 to -11.92) | -15.14 (-18.43 to -11.73) |
| Week 52 | -12.27 (-15.92 to -8.46) | -13.13 (-16.77 to -9.33) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
| percent change | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | -3.88 (-4.74 to -3.02) | -5.26 (-6.11 to -4.41) |
| Week 52 | -4.25 (-5.29 to -3.21) | -5.96 (-6.98 to -4.93) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
| percent | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | -2.26 (-2.83 to -1.70) | -2.63 (-3.22 to -2.04) |
| Week 52 | -1.49 (-2.18 to -0.77) | -1.68 (-2.41 to -0.96) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
| mg/dL | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | -9.37 (-15.80 to -2.94) | -15.06 (-21.62 to -8.51) |
| Week 52 | -11.62 (-18.62 to -4.62) | -12.93 (-19.99 to -5.88) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.
| mg/dL | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | -2.33 (-11.18 to 6.51) | -10.08 (-19.04 to -1.12) |
| Week 52 | -6.40 (-15.45 to 2.64) | -5.24 (-14.32 to 3.83) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin
| percentage of participants | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | 60.8 (48.8 to 72.0) | 61.3 (49.4 to 72.4) |
| Week 52 | 51.4 (39.4 to 63.1) | 41.3 (30.1 to 53.3) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin
| percentage of participants | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | 62.2 (50.1 to 73.2) | 66.7 (54.8 to 77.1) |
| Week 52 | 51.4 (39.4 to 63.1) | 45.3 (33.8 to 57.3) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin
| percentage of participants | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | 9.5 (3.9 to 18.5) | 5.3 (1.5 to 13.1) |
| Week 52 | 6.8 (2.2 to 15.1) | 2.7 (0.3 to 9.3) |
To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin
| mmHg | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Week 24 | -5.8 (-11.2 to -0.3) | -12.0 (-19.0 to -5.0) |
| Week 52 | -9.8 (-15.1 to -4.5) | -14.2 (-20.7 to -7.6) |
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
| bpm | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Vital Signs (Heart Rate) | -0.3 ± 10.07 | 0.4 ± 8.89 |
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
| Participants | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Baseline — NORMAL | 65 | 67 |
| Baseline — ABNORMAL | 11 | 8 |
| Baseline — NOT REPORTED | 0 | 0 |
| Week 52 — NORMAL | 69 | 67 |
| Week 52 — ABNORMAL | 5 | 8 |
| Week 52 — NOT REPORTED | 2 | 0 |
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
| Participants | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Hematocrit (> 55%) | 1 | 0 |
| Hemoglobin (> 18g/dL) | 2 | 1 |
| Creatinine (>1.5 x ULN pre Rx) | 0 | 1 |
| Creatin kinase (> 5x ULN) | 1 | 1 |
| Bicarbonate (<= 13 mEq/L) | 1 | 0 |
| P (<=1.8/2.1mg/dL for age<=/>65) | 1 | 1 |
| UACR (> 1800mg/g) | 0 | 1 |
To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.
| mmHg | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| Change from baseline in SBP(mmHg) at Week 52 | -3.4 ± 11.41 | -2.9 ± 12.55 |
| Change from baseline in DBP(mmHg) at Week 52 | -0.6 ± 8.21 | -1.0 ± 7.89 |
Collected over 1 year. Non-serious adverse event (AE): onset on or after the 1st day of dose up to on or prior to the last day of dose plus 4 days. Serious AE: onset on or after the 1st day of dose up to on or prior to the last day of dose plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin 5mg + Insulin | 0/76 (0%) | 7/76 (9.2%) | 66/76 (86.8%) |
| Dapagliflozin 10mg + Insulin | 0/75 (0%) | 3/75 (4%) | 55/75 (73.3%) |
| Event | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| DIABETIC KETOACIDOSISMetabolism and nutrition disorders | 2/76 | 1/75 |
| VITREOUS HAEMORRHAGEEye disorders | 0/76 | 1/75 |
| COLITISGastrointestinal disorders | 0/76 | 1/75 |
| HYPOGLYCAEMIC COMANervous system disorders | 0/76 | 1/75 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/76 | 0/75 |
| HEPATIC FUNCTION ABNORMALHepatobiliary disorders | 1/76 | 0/75 |
| GASTROENTERITISInfections and infestations | 1/76 | 0/75 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 1/76 | 0/75 |
| ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions | 1/76 | 0/75 |
| Event | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 25/76 | 32/75 |
| PHARYNGITISInfections and infestations | 5/76 | 9/75 |
| GASTROENTERITISInfections and infestations | 7/76 | 8/75 |
| KETOSISMetabolism and nutrition disorders | 4/76 | 7/75 |
| POLLAKIURIARenal and urinary disorders | 7/76 | 6/75 |
| HEADACHENervous system disorders | 4/76 | 6/75 |
| BACK PAINMusculoskeletal and connective tissue disorders | 6/76 | 1/75 |
| DENTAL CARIESGastrointestinal disorders | 0/76 | 5/75 |
| ECZEMASkin and subcutaneous tissue disorders | 4/76 | 4/75 |
| THIRSTGeneral disorders | 4/76 | 4/75 |
Randomized set
| Age, Continuous(years) | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin | Total |
|---|---|---|---|
| Mean | 47.7 ± 12.85 | 48.9 ± 12.93 | 48.3 ± 12.86 |
| Sex: Female, Male(Participants) | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin | Total |
|---|---|---|---|
| Female | 33 | 42 | 75 |
| Male | 43 | 33 | 76 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin | Total |
|---|---|---|---|
| Asian | 76 | 75 | 151 |
| Body Mass Index(kg/m2) | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin | Total |
|---|---|---|---|
| Mean | 25.28 ± 3.635 | 24.66 ± 2.806 | 24.97 ± 3.254 |
| Duration of T1DM(years) | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin | Total |
|---|---|---|---|
| Mean | 14.60 ± 8.420 | 15.94 ± 10.328 | 15.27 ± 9.409 |
| HbA1c(Percent) | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin | Total |
|---|---|---|---|
| Mean | 8.43 ± 0.711 | 8.40 ± 0.715 | 8.42 ± 0.711 |
| C-peptide(Participants) | Dapagliflozin 5mg + Insulin | Dapagliflozin 10mg + Insulin | Total |
|---|---|---|---|
| < 0.1 ng/mL | 63 | 65 | 128 |
| >= 0.1 ng/mL | 13 | 10 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Jun 2017, 19 months.
Results were first posted in Apr 2019, 1 year 9 months after primary completion.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 19 months is above that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin